Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

Author(s):

Sebastian E Sattui, Christian Dejaco, Kerri Ford, Stefano Fiore, Sebastian H Unizony, Fenglong Xie, Jeffrey R Curtis

Abstract or description:

Sebastian E Sattui¹, Christian Dejaco^2,3, Kerri Ford⁴, Stefano Fiore⁵, Sebastian H Unizony⁶, Fenglong Xie^7,8, Jeffrey R Curtis^7,8

¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA; ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Medical University, Graz, Austria; ³Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy; ⁴Sanofi, Cambridge, MA, USA; ⁵Sanofi, Bridgewater, NJ, USA; ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ⁷The University of Alabama at Birmingham, Birmingham, AL, USA; ⁸Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA

REFERENCES

1. Sattui SE, et al. Rheumatology (Oxford). 2022;61(11):4455–64.
2. Motta F, et al. Front Immunol. 2020;11:576134.
3. Spiera RF, et al. N Engl J Med. 2023;389(14):1263–72.
4. Curtis JR, et al. CCR-E 2024. Poster presentation.
5. Kim DH, et al. J Gerontol A Biol Sci Med Sci. 2019;74(8):1271–6.
6. Halawa OA, et al. Ophthalmology. 2023;130(6):646–54.